By clicking yes you will be able to see content available for healthcare professionals only.
Våre nettsider benytter cookies. Dersom cookien ikke er nødvendig for at nettsiden vår skal fungere,
vil den ikke lagres på din enhet med mindre du samtykker til dette.
Les mer om cookies her.
Ikke satt ennå.
Takeda is pleased to invite you and your colleagues to a virtual scientific meeting on Hypoparathyroidism.The lecture will cover topics relating to COVID-19, latest RACE trial data and the Burden of Illness of Chronic Hypoparathyroidism.
Erik Fink Eriksen is currently practising as doctor in endocrinology and internal medicine at Spesialistsenteret, Pilestredet Park, Oslo. His previous appointments includes: Professor of Endocrinology at Oslo University Hospital, Global Product Medical Director (Arthritis and Bone Therapeutic Area) at Novartis Pharmaceuticals, where he was responsible for the global development programme and approval of the osteoporosis drug Aclasta; Global Medical Director, Eli Lilly & Co., Indianapolis, USA (2002–2005), where he was responsible for the approval of PTH(1-34) (Forsteo) as osteoporosis treatment; Department Head and Consultant, Department of Endocrinology and Internal Medicine, Aarhus Amtssygehus (1995–2001), and Assoc. Professor, University of Aarhus (1995).
He has authored or co-authored over 270 publications and 3 books. His work is cited 980 times per year and each paper has an average citation index of 42 (H-index 59).
He has received the Gold medal in Biochemistry at Århus University 1979 and the Young Investigator Award of the American Society of Bone and Mineral Research 1987. 2001 he received a NOVO-Nordisk research grant for postdoctoral researchers. In the year 2002 two of his papers were among the 21 most cited in the last 25 years in the Journal of Bone and Mineral Research. His team at Novartis received the Good Clinical Practice Award 2007.
We hope that you find this invitation and topics appealing and that you have interest and opportunity to attend the meeting. For further questions please contact the undersigned.
Baard UlsteinKey Account Manager Rare Diseases Takedabaard.email@example.com 10 182